Search

Showing "11154" results for ""

ICAAC: Tenofovir and Trizivir effective and well-tolerated in patients who fail first regimen

ICAAC: Resistance found in one in seven of treatment-naive US patients

ICAAC: Saquinavir and ritonavir must be taken simultaneously for best saquinavir levels

ICAAC: Combination of tenofovir and Trizivir as effective and tolerable as Combivir / efavirenz

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

ICAAC: Glaxo unveils chemokine blocker as interest in new drug class hots up

US HIV treatment guidelines revised

ICAAC: Rapid HIV disease progression in injecting drug users in Ukraine

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: Kaletra: stability and potency decline rapidly in hot climates

An integrated approach to HIV and TB care in adults in resource-limited settings, part 1

ICAAC: HIV / HCV coinfected patients with fibrosis get little benefit and a lot of side-effects from interferon / ribavirin

ICAAC: Pegylated interferon-alpha 2a produces good results in HIV / HCV patients with genotype 1

Detectable viral load risk factor for new illness in those who start HAART with CD4 below 50

Major UK HIV clinic finds one in five patients diagnosed with CD4 count below 50

HCV co-infection hastens HIV disease progression, finds US veterans study

Risk factors for gynaecomastia include hepatitis C, fat loss, and low testosterone

Ranbaxy announces withdrawal of all generic ARVs from WHO list

Receive the latest HIV research and conference news

Showing "11154" results for ""

ICAAC: Tenofovir and Trizivir effective and well-tolerated in patients who fail first regimen

ICAAC: Resistance found in one in seven of treatment-naive US patients

ICAAC: Saquinavir and ritonavir must be taken simultaneously for best saquinavir levels

ICAAC: Combination of tenofovir and Trizivir as effective and tolerable as Combivir / efavirenz

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

ICAAC: Glaxo unveils chemokine blocker as interest in new drug class hots up

US HIV treatment guidelines revised

ICAAC: Rapid HIV disease progression in injecting drug users in Ukraine

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: Kaletra: stability and potency decline rapidly in hot climates

An integrated approach to HIV and TB care in adults in resource-limited settings, part 1

ICAAC: HIV / HCV coinfected patients with fibrosis get little benefit and a lot of side-effects from interferon / ribavirin

ICAAC: Pegylated interferon-alpha 2a produces good results in HIV / HCV patients with genotype 1

Detectable viral load risk factor for new illness in those who start HAART with CD4 below 50

Major UK HIV clinic finds one in five patients diagnosed with CD4 count below 50

HCV co-infection hastens HIV disease progression, finds US veterans study

Risk factors for gynaecomastia include hepatitis C, fat loss, and low testosterone

Ranbaxy announces withdrawal of all generic ARVs from WHO list

Receive the latest HIV research and conference news